100% tariffs on drugs
What happened
President Trump signed an executive order that allows tariffs of up to 100% on certain imported patented drugs as a lever to force manufacturers to onshore production. The order includes exemptions but the pharmaceutical industry has already pushed back, setting up a fresh policy fight that could affect supply chains and consumer costs for brand‑name medicines. (ksbw.com) (markets.financialcontent.com)
Why it matters
President Trump signed an executive order on April 2, 2026 that sets a baseline 100% duty on certain imported patented medicines and some of their ingredients; the administration says a first group of large firms will face that duty beginning July 31, 2026 and other companies will begin facing it on September 29, 2026. (whitehouse.gov) (supplychaindive.com) The order creates a set of exemptions and lower rates as incentives: companies that both agree to onshore manufacturing and accept the administration’s “most favored nation” pricing (meaning the U.S. would get prices no higher than the lowest price the company charges in other wealthy countries) can avoid tariffs through January 20, 2029; companies that only commit to onshoring would pay a 20% tariff that the order says rises toward 100% over four years. (whitehouse.gov) (supplychaindive.com) The legal vehicle named in the proclamation is Section 232 of the Trade Expansion Act of 1962, a law that lets the Commerce Secretary investigate whether imports threaten national security and recommend import restrictions; the Commerce report cited by the White House found that about 53% of patented medicines distributed in the U.S. are produced overseas and that only about 15% of patented active pharmaceutical ingredients by volume are made domestically. (whitehouse.gov) The White House says the looming tariffs already prompted roughly $400 billion in new investment commitments to U.S. drug manufacturing, and it lists 17 major firms as an initial focus — companies that have previously been the target of the administration’s pricing and onshoring push (the 17 include AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi and others). (whitehouse.gov) (biopharminternational.com) The package also carves out lower tariffs for drugs made in countries that have recent trade arrangements with the U.S. — the administration set a 15% cap for covered products from the European Union, Japan, South Korea, Switzerland and Liechtenstein and a lower, time‑limited rate for the United Kingdom — and it explicitly excludes generic drugs and biosimilars from the duty for now. (supplychaindive.com) (whitehouse.gov) Industry groups immediately pushed back, with the trade group PhRMA saying tariffs “will increase costs and could jeopardize billions in U.S. investments announced in the last year,” and other analysts warning the levy could raise prices at the pharmacy and complicate supply chains that currently rely heavily on foreign production of drug ingredients. (phrma.org) (latimes.com)
Key numbers
- President Trump signed an executive order that allows tariffs of up to 100% on certain imported patented drugs as a lever to force manufacturers to onshore production.
- would get prices no higher than the lowest price the company charges in other wealthy countries) can avoid tariffs through January 20, 2029; companies that only commit to onshoring would pay a 20% tariff that the order says rises toward 100% over four years.
- are produced overseas and that only about 15% of patented active pharmaceutical ingredients by volume are made domestically.
- (whitehouse.gov) The White House says the looming tariffs already prompted roughly $400 billion in new investment commitments to U.S.
What happens next
- (supplychaindive.com) (whitehouse.gov) Industry groups immediately pushed back, with the trade group PhRMA saying tariffs “will increase costs and could jeopardize billions in U.S.
- investments announced in the last year,” and other analysts warning the levy could raise prices at the pharmacy and complicate supply chains that currently rely heavily on foreign production of drug ingredients.
- The order includes exemptions but the pharmaceutical industry has already pushed back, setting up a fresh policy fight that could affect supply chains and consumer costs for brand‑name medicines.
Quick answers
What happened in 100% tariffs on drugs?
President Trump signed an executive order that allows tariffs of up to 100% on certain imported patented drugs as a lever to force manufacturers to onshore production. The order includes exemptions but the pharmaceutical industry has already pushed back, setting up a fresh policy fight that could affect supply chains and consumer costs for brand‑name medicines. (ksbw.com) (markets.financialcontent.com)
Why does 100% tariffs on drugs matter?
President Trump signed an executive order on April 2, 2026 that sets a baseline 100% duty on certain imported patented medicines and some of their ingredients; the administration says a first group of large firms will face that duty beginning July 31, 2026 and other companies will begin facing it on September 29, 2026. (whitehouse.gov) (supplychaindive.com) The order creates a set of exemptions and lower rates as incentives: companies that both agree to onshore manufacturing and accept the administration’s “most favored nation” pricing (meaning the U.S. would get prices no higher than the lowest price the company charges in other wealthy countries) can avoid tariffs through January 20, 2029; companies that only commit to onshoring would pay a 20% tariff that the order says rises toward 100% over four years. (whitehouse.gov) (supplychaindive.com) The legal vehicle named in the proclamation is Section 232 of the Trade Expansion Act of 1962, a law that lets the Commerce Secretary investigate whether imports threaten national security and recommend import restrictions; the Commerce report cited by the White House found that about 53% of patented medicines distributed in the U.S. are produced overseas and that only about 15% of patented active pharmaceutical ingredients by volume are made domestically. (whitehouse.gov) The White House says the looming tariffs already prompted roughly $400 billion in new investment commitments to U.S. drug manufacturing, and it lists 17 major firms as an initial focus — companies that have previously been the target of the administration’s pricing and onshoring push (the 17 include AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi and others). (whitehouse.gov) (biopharminternational.com) The package also carves out lower tariffs for drugs made in countries that have recent trade arrangements with the U.S. — the administration set a 15% cap for covered products from the European Union, Japan, South Korea, Switzerland and Liechtenstein and a lower, time‑limited rate for the United Kingdom — and it explicitly excludes generic drugs and biosimilars from the duty for now. (supplychaindive.com) (whitehouse.gov) Industry groups immediately pushed back, with the trade group PhRMA saying tariffs “will increase costs and could jeopardize billions in U.S. investments announced in the last year,” and other analysts warning the levy could raise prices at the pharmacy and complicate supply chains that currently rely heavily on foreign production of drug ingredients. (phrma.org) (latimes.com)
